@article{6e1af718f1e54f68bca4c3e87c83d447,
title = "Overcoming obstacles to repurposing for neurodegenerative disease",
abstract = "Repurposing Food and Drug Administration (FDA)-approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer's Drug Discovery Foundation (ADDF) and the Michael J. Fox Foundation for Parkinson's Research (MJFF) convened an advisory panel in October 2013 to understand stakeholder perspectives related to repurposing FDA-approved drugs for neurodegenerative diseases. Here, we present opportunities on how philanthropy, industry, and government can begin to address these challenges, promote policy changes, and develop targeted funding strategies to accelerate the potential of FDA-approved repurposed drugs.",
author = "Shineman, {Diana W.} and John Alam and Margaret Anderson and Black, {Sandra E.} and Carman, {Aaron J.} and Cummings, {Jeffrey L.} and Dacks, {Penny A.} and Dudley, {Joel T.} and Frail, {Donald E.} and Allan Green and Lane, {Rachel F.} and Debra Lappin and Tanya Simuni and Stefanacci, {Richard G.} and Todd Sherer and Fillit, {Howard M.}",
note = "Funding Information: Several groups today are funding such pilot trials with the hopes of catalyzing larger interest in repurposed candidates. Cures Within Reach is a foundation exclusively focused on supporting repurposing studies. The ADDF, MJFF, Alzheimer{\textquoteright}s Society (UK), Cure Parkinson{\textquoteright}s Trust, the Multiple Myeloma Research Foundation and others have funded repurposing trials and have recently announced funding opportunities for repurposed drugs. Many academic centers are also leading repurposing efforts in collaboration with government initiatives. Through the “Learning Collaborative,” the Leukemia Lymphoma Society is working with the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) and the University of Kansas on repurposing Auranofin for chronic lymphocytic leukemia. Thalidomide, infamous for causing severe birth defects when used for morning sickness in the 1950s, is now a widely prescribed and valuable treatment for leprosy and multiple myeloma thanks in part to the research findings from the academic community that resulted in Celgene seeking FDA approval for the new indications.10 Methotrexate is another example of an approved drug which found a new life as a treatment for rheumatoid arthritis and is currently improving the quality of life for hundreds of thousands of patients.11 Funding Information: Dr Frail is an employee of AstraZeneca. Dr. Simuni reports personal fees from Abbvie, personal fees from Allergan, personal fees from Boehringer Ingelheim, grants and personal fees from GE Medical, personal fees from Harbor, personal fees from Ibsen, grants and personal fees from IMPAX, personal fees from Merz Inc., grants and personal fees from National Parkinson Foundation, personal fees from Navidea, personal fees from Novartis, grants, personal fees and other from TEVA, personal fees from UCB Pharma, personal fees from US World Meds, grants from SYNOSIA, grants from SERONO, grants from Cogane, grants from NIH, grants from Dixon Foundation, grants from Michael J. Fox Foundation, grants from PARS Studies, grants from Michael J. Fox Foundation PPMI Study, outside the submitted work. Publisher Copyright: {\textcopyright} 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.",
year = "2014",
month = jul,
doi = "10.1002/acn3.76",
language = "English (US)",
volume = "1",
pages = "512--518",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "John Wiley and Sons Inc.",
number = "7",
}